Hainan Shuangcheng Pharmaceut - Asset Resilience Ratio
Hainan Shuangcheng Pharmaceut (002693) has an Asset Resilience Ratio of 3.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Hainan Shuangcheng Pharmaceut for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Hainan Shuangcheng Pharmaceut's Asset Resilience Ratio has changed over time. See 002693 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hainan Shuangcheng Pharmaceut's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Hainan Shuangcheng Pharmaceut worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥26.22 Million | 3.29% |
| Total Liquid Assets | CN¥26.22 Million | 3.29% |
Asset Resilience Insights
- Limited Liquidity: Hainan Shuangcheng Pharmaceut maintains only 3.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Shuangcheng Pharmaceut Industry Peers by Asset Resilience Ratio
Compare Hainan Shuangcheng Pharmaceut's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Hainan Shuangcheng Pharmaceut (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Hainan Shuangcheng Pharmaceut.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥2.83K ≈ $413.53 |
CN¥783.87 Million ≈ $114.70 Million |
-3.55pp |
| 2023-12-31 | 3.55% | CN¥28.52 Million ≈ $4.17 Million |
CN¥803.25 Million ≈ $117.54 Million |
-11.14pp |
| 2022-12-31 | 14.69% | CN¥133.81 Million ≈ $19.58 Million |
CN¥911.02 Million ≈ $133.31 Million |
+8.20pp |
| 2021-12-31 | 6.48% | CN¥55.40 Million ≈ $8.11 Million |
CN¥854.56 Million ≈ $125.05 Million |
-3.90pp |
| 2020-12-31 | 10.38% | CN¥94.25 Million ≈ $13.79 Million |
CN¥907.68 Million ≈ $132.82 Million |
+4.83pp |
| 2019-12-31 | 5.55% | CN¥52.80 Million ≈ $7.73 Million |
CN¥950.98 Million ≈ $139.16 Million |
-6.94pp |
| 2018-12-31 | 12.50% | CN¥139.98 Million ≈ $20.48 Million |
CN¥1.12 Billion ≈ $163.93 Million |
+1.80pp |
| 2017-12-31 | 10.69% | CN¥147.25 Million ≈ $21.55 Million |
CN¥1.38 Billion ≈ $201.52 Million |
+10.26pp |
| 2016-12-31 | 0.43% | CN¥5.00 Million ≈ $731.66K |
CN¥1.17 Billion ≈ $170.55 Million |
+0.21pp |
| 2015-12-31 | 0.22% | CN¥3.37 Million ≈ $493.14K |
CN¥1.55 Billion ≈ $226.84 Million |
-40.06pp |
| 2014-12-31 | 40.27% | CN¥380.00 Million ≈ $55.61 Million |
CN¥943.54 Million ≈ $138.07 Million |
-- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmace… Read more